Opendata, web and dolomites

CARAMBA SIGNED

SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma – a rare hematologic disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CARAMBA project word cloud

Explore the words cloud of the CARAMBA project. It provides you a very rough idea of what is the project "CARAMBA" about.

therapy    expressed    demand    caramba    successful    myeloma    market    validated    free    ensured    highlighted    cells    economically    socioeconomically    prepared    patients    patient    confident    incurable    indication    complete    receptor    treatment    equally    clinical    ec    uniformly    burden    caregivers    edge    substantially    trial    proposing    families    leukemia    proprietary    immunotherapy    chimeric    manufacturing    commercially    multiple    express    antigen    substantial    designation    breakthrough    medicinal    desirable    cutting    dna    socioeconomic    rare    hematologic    received    efficacy    group    men    recruitment    beauty    excellence    building    mpe    orphan    gene    revolutionary    safety    slamf7    sleeping    malignancy    authorization    reduces    cd19    attractive    rapid    virus    sme    transfer    sustainable    conduct    tackle    engineered    unprecedented    synthetic    advocacy    women    therapeutically    car    investigators    curative    minicircles    diseases    cell    participation    centres    proof    technologies    lymphoma   

Project "CARAMBA" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT 

Organization address
address: JOSEF-SCHNEIDER-STRASSE 2
city: WURZBURG
postcode: 97080
website: www.uk-wuerzburg.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.caramba-cart.eu
 Total cost 6˙097˙875 €
 EC max contribution 6˙097˙875 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2022-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT DE (WURZBURG) coordinator 2˙021˙250.00
2    OSPEDALE SAN RAFFAELE SRL IT (MILANO) participant 893˙125.00
3    DRK-BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH DE (MANNHEIM) participant 685˙000.00
4    UNIVERSIDAD DE NAVARRA ES (PAMPLONA) participant 624˙375.00
5    T-CURX GMBH DE (WURZBURG) participant 503˙750.00
6    CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE FR (LILLE) participant 384˙375.00
7    BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL DE (LANGEN) participant 342˙875.00
8    ARTTIC FR (PARIS) participant 327˙500.00
9    NBE-THERAPEUTICS AG CH (BASEL) participant 200˙000.00
10    MYELOMA PATIENTS EUROPE AISBL BE (Charleroi) participant 115˙625.00

Map

 Project objective

CARAMBA is proposing to use the revolutionary CAR-T cell technology to tackle multiple myeloma, a rare and incurable hematologic malignancy. Myeloma is associated with a substantial socioeconomic burden and there is a strong demand by patients, their families and caregivers for a curative myeloma treatment. The CARAMBA investigators will conduct a phase I/II clinical trial of immunotherapy with patient-derived T cells that are engineered to express a synthetic chimeric antigen receptor (CAR) specific for the myeloma antigen SLAMF7. SLAMF7 is uniformly expressed on all myeloma cells in every patient, and SLAMF7 CAR-T cells will be equally effective in women and men. The efficacy and safety of SLAMF7 CAR-T cells has been validated by the coordinator in comprehensive pre-clinical testing which highlighted their unprecedented curative potential. SLAMF7 CAR-T cells have received an orphan designation for the indication multiple myeloma by the EC. The successful conduct, rapid and complete recruitment into the clinical trial is ensured by participation of 4 clinical myeloma centres of excellence in 4 EU member states, and the largest myeloma patient advocacy group in Europe, MPE. The SME partners in CARAMBA are prepared to develop the SLAMF7 CAR product all the way to market authorization. CAR-T cell therapy has been recognized as a ‘Breakthrough Therapy’ and clinical proof-of-concept obtained with CD19 CAR-T cells in leukemia and lymphoma. CARAMBA is building on novel and proprietary, cutting-edge CAR technologies including virus-free Sleeping Beauty CAR gene-transfer from DNA minicircles which substantially reduces the cost of CAR-T cell manufacturing, making it an economically viable and sustainable medicinal product. We are confident, that if funded, CARAMBA will accomplish its objective to establish the role of CAR-T cell therapy as a therapeutically effective, commercially attractive and socioeconomically desirable treatment in myeloma and other rare diseases.

 Publications

year authors and title journal last update
List of publications.
2018 Michael Hudecek, Zoltán Ivics
Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system
published pages: 100-108, ISSN: 0959-437X, DOI: 10.1016/j.gde.2018.06.003
Current Opinion in Genetics & Development 52 2019-09-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARAMBA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARAMBA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More